Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection  Johannes Vermehren, James S. Park, Ira M. Jacobson, Stefan Zeuzem  Journal of Hepatology  Volume 69, Issue 5, Pages 1178-1187 (November 2018) DOI: 10.1016/j.jhep.2018.07.002 Copyright © 2018 Terms and Conditions

Fig. 1 Antiviral treatment algorithm in challenging HCV cases. Recently introduced pangenotypic regimens have addressed critical remaining gaps in the capacity to treat challenging populations with HCV infection. See text and tables for indications and recommendations, including variations in regulatory approvals and expert guidelines, in specific subgroups, e.g. treatment-naive vs. experienced, non-cirrhotics vs. cirrhotics, baseline resistance-associated substitutions (RAS), and DAA failures. DAA, direct-acting antiviral; EBR/GZR, elbasvir/grazoprevir; G/P, glecaprevir/pibrentasvir; GT, genotype; HCV, hepatitis C virus; NS3 exp., patients with prior HCV NS3/4A protease inhibitor failure; NS5A exp., patients with prior HCV NS5A-inhibitor failure; P/R exp., patients with prior pegylated interferon and ribavirin failure; SOF/LDV, sofosbuvir/ledipasvir; SOF/VEL, sofosbuvir/velpatasvir; SOF/VEL/VOX, sofosbuvir/velpatasvir/voxilaprevir; RBV, ribavirin. Journal of Hepatology 2018 69, 1178-1187DOI: (10.1016/j.jhep.2018.07.002) Copyright © 2018 Terms and Conditions